823PEfficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). (23rd October 2018) - Gajate Borau, P; Martin Marino, A; Gallegos Sancho, I; Villa Guzman, J C; Velastegui, A; Alonso Gordoa, T; Castellano, D; Rubio Romero, G; Pinto Marin, A; Villalobos Leon, L; Maximiano Alonso, C; Sotelo-Lezama, M J; et al.